Q3 EPS Estimates for OTCMKTS:BSEM Increased by Analyst

BioStem Technologies, Inc. (OTCMKTS:BSEM) – Analysts at Zacks Small Cap lifted their Q3 2024 earnings estimates for shares of BioStem Technologies in a research note issued on Thursday, October 17th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings per share of $0.36 for the quarter, up from their prior forecast of $0.31. The consensus estimate for BioStem Technologies’ current full-year earnings is $1.13 per share. Zacks Small Cap also issued estimates for BioStem Technologies’ Q4 2024 earnings at $0.38 EPS.

BioStem Technologies Trading Down 4.3 %

BioStem Technologies stock opened at 11.95 on Friday. The firm has a market capitalization of $194.64 million, a P/E ratio of 30.64 and a beta of 0.05. BioStem Technologies has a 52 week low of 2.26 and a 52 week high of 15.50. The stock has a fifty day moving average price of 10.84 and a 200 day moving average price of 9.79.

BioStem Technologies (OTCMKTS:BSEM) last posted its quarterly earnings data on Monday, August 12th. The company reported 0.30 EPS for the quarter, topping analysts’ consensus estimates of 0.12 by 0.18. The company had revenue of 74.49 million for the quarter, compared to analysts’ expectations of 43.99 million.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.